Dominantly Inherited Alzheimer Network: facilitating research and clinical trials
Open accessAbstract
The Dominantly Inherited Alzheimer Network (DIAN) is an international registry of individuals at risk for developing autosomal dominant Alzheimer's disease (AD). Its primary aims are to investigate the temporal ordering of AD pathophysiological changes that occur in asymptomatic mutation carriers and to identify those markers that herald the transition from cognitive normality to symptomatic AD. DIAN participants undergo longitudinal evaluations, including clinical and cognitive assessments and measurements of molecular and imaging AD biomarkers. This review details the unique attributes of DIAN as a model AD biomarker study and how it provides the infrastructure for innovative research projects, including clinical trials. The recent design and launch of the first anti-amyloid-beta secondary prevention trial in AD, led by the related DIAN Trials Unit, also are discussed.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The DIAN cohort consists of people from families with highly penetrant autosomal-dominant mutations in APP, PSEN1, or PSEN2.
“DIAN participants are members of families carrying highly penetrant autosomal-dominant mutations in the genes encoding the amyloid beta precursor protein (APP) or presenilin 1 (PSEN1) or 2 (PSEN2)19.”
From Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease (2019) · cites this paper as [19]
Autosomal dominant AD is well suited to study biomarker trajectories due to the virtually complete penetrance of the mutations and consistency of symptom onset within families.
“Autosomal dominant AD (ADAD) is well suited to study biomarker trajectories due to the virtually complete penetrance of the mutations and consistency of symptom onset within families4,5.”
From Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works
Self-citationAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1× · see citing works
“Even with the publication of the National Institute on Aging (NIA)-Alzheimer’s Association diagnostic criteria and guidelines for preclinical AD, mild cognitive impairment (MCI) due to AD, and symptomatic AD [33-35], many researchers and clinicians still consider the term preclinical AD to encompass prodromal AD, MCI,…”
BackgroundSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · see citing works
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396 · see citing works
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · see citing works
Self-citationAlzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642 · see citing works
Albert, M., DeKosky, S. T., Dickson, D. W., Dubois, B., Feldman, H., Fox, N. C., Gamst, A. C., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.11.1.96 · Cited by 2,630 · see citing works
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599 · see citing works
Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease
Gómez-Isla, T., Price, J. L., McKeel Jr., D. W., Morris, J. C., Growdon, J. H., & Hyman, B. T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04491.1996 · Cited by 1,796 · cited 1× · see citing works
“AD pathology is present in the brain many years before the onset of clinical symptoms [5-11].”
BackgroundSelf-citationAlzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424 · see citing works
Self-citationAlzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351 · see citing works
Neuropathology of older persons without cognitive impairment from two community-based studies
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336 · see citing works
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · see citing works
Self-citationLongitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22248 · Cited by 833 · see citing works
Neuropathology of Cognitively Normal Elderly
Knopman, D. S., Parisi, J. E., Salviati, A., Floriach-Robert, M., Boeve, B. F., Ivnik, R. J., Smith, G. E., Dickson, D. W., Johnson, K. A., Petersen, L. E., et al. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.11.1087 · Cited by 674 · see citing works
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease
Price, J. L., McKeel, D. W., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., Hansen, L. A., Petersen, R. C., Parisi, J. E., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.002 · Cited by 661 · see citing works
Self-citationNeuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer Disease
Price, J. L., Ko, A. I., Wade, M. J., Tsou, S. K., McKeel, D. W., & Morris, J. C. (2001) · Archives of Neurology · doi:10.1001/archneur.58.9.1395 · Cited by 596 · see citing works
Self-citationBateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., Salloway, S., Sperling, R. A., Windisch, M., & Xiong, C. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt59 · Cited by 573 · see citing works
Self-citationTesting the Right Target and Right Drug at the Right Stage
Sperling, R. A., Jack, C. R., & Aisen, P. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002609 · Cited by 550 · see citing works
Reiman, E. M., Quiroz, Y. T., Fleisher, A. S., Chen, K., Velez-Pardo, C., Jimenez-Del-Rio, M., Fagan, A. M., Shah, A. R., Alvarez, S., Arbelaez, A., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70228-4 · Cited by 541 · see citing works
Kuperstein, I., Broersen, K., Benilova, I., Rozenski, J., Jonckheere, W., Debulpaep, M., Vandersteen, A., Segers‐Nolten, I., Van Der Werf, K., Subramaniam, V., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.211 · Cited by 532 · see citing works
Morris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., Fagan, A. M., Holtzman, D. M., & Mintun, M. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.269 · Cited by 476 · see citing works
Self-citationLocus‐specific mutation databases for neurodegenerative brain diseases
Cruts, M., Theuns, J., & Broeckhoven, C. V. (2012) · Human Mutation · doi:10.1002/humu.22117 · Cited by 462 · see citing works
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
(2012) · New England Journal of Medicine · doi:10.1056/nejmx120056 · Cited by 382 · see citing works
Lopera, F. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340027028 · Cited by 351 · see citing works
Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments
Reiman, E. M., Langbaum, J. B. S., Fleisher, A., Caselli, R. J., Chen, K., Ayutyanont, N., Quiroz, Y. T., Kosik, K. S., Lopera, F. J., & Tariot, P. N. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-0059 · Cited by 337 · see citing works
(2006) · PubMed · Cited by 269 · see citing works
Fox, N. C. (1998) · Brain · doi:10.1093/brain/121.9.1631 · Cited by 263 · see citing works
Lopera, F. J. (1997) · JAMA · doi:10.1001/jama.277.10.793 · Cited by 255 · see citing works
Fleisher, A., Chen, K., Quiroz, Y. T., Jakimovich, L. J., Gomez, M. G., Langois, C. M., Langbaum, J. B. S., Ayutyanont, N., Roontiva, A., Thiyyagura, P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70227-2 · Cited by 242 · see citing works
McKhann, G. M., Knopman, D. S., Chertkow, H. M., Hyman, B. T., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mohs, R. C., Morris, J. C., et al. (2011) · Alzheimer s & Dementia · Cited by 240 · see citing works
Self-citationMorris, J. C., Aisen, P. S. S., Bateman, R. J., Benzinger, T. L. S., Cairns, N. J., Fagan, A. M., Ghetti, B. F., Goate, A., Holtzman, D. M., Klunk, W. E., et al. (2012) · Clinical Investigation · doi:10.4155/cli.12.93 · Cited by 205 · see citing works
Self-citationMcGuire, S. (2013) · Advances in Nutrition · doi:10.3945/an.113.003889 · Cited by 196 · see citing works
Snider, B. J., Norton, J. B., Coats, M. A., Chakraverty, S., Hou, C. E., Jervis, R., Lendon, C. L., Goate, A., McKeel, D. W., & Morris, J. C. (2005) · Archives of Neurology · doi:10.1001/archneur.62.12.1821 · Cited by 129 · see citing works
Self-citationWallon, D., The collaborators of the GMAJ project, Rousseau, S., Rovelet‐Lecrux, A., Quillard‐Muraine, M., Guyant‐Maréchal, L., Martinaud, O., Pariente, J., Puel, M., Rollin‐Sillaire, A., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120172 · Cited by 124 · see citing works
Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease
Carrillo, M. C., Brashear, H. R., Logovinsky, V., Ryan, J. M., Feldman, H., Siemers, E., Abushakra, S. R., Hartley, D. M., Petersen, R. C., Khachaturian, A. S., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.12.004 · Cited by 124 · see citing works
(2013) · PubMed · Cited by 69 · see citing works
Familial Alzheimer's disease: Site of mutation influences clinical phenotype
Lippa, C. F., Swearer, J. M., Kane, K., Nochlin, D., Bird, T. D., Ghetti, B. F., Nee, L. E., George‐Hyslop, P. S., Pollen, D. A., & Drachman, D. A. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200009)48:3 · Cited by 67 · see citing works
Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology
Monsell, S. E., Mock, C., Roe, C. M., Ghoshal, N., Morris, J. C., Cairns, N. J., & Kukull, W. A. (2013) · Neurology · doi:10.1212/wnl.0b013e318295d7a1 · Cited by 56 · see citing works
Self-citationAcceleration of cortical thinning in familial Alzheimer's disease
Knight, W. D., Kim, L. G., Douiri, A., Frost, C. D., Rossor, M. N., & Fox, N. C. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.11.013 · Cited by 47 · see citing works
Age of onset in familial early onset Alzheimer's disease correlates with genetic aetiology
MULLAN, M. J., Houlden, H., Crawford, F., Kennedy, A. M., Rogues, P. K., & Rossor, M. N. (1993) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320480303 · Cited by 45 · see citing works
Ringman, J. M. (2005) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988705281878 · Cited by 37 · see citing works
Measuring Target Effect of Proposed Disease-Modifying Therapies in Alzheimer's Disease
Bateman, R. J., & Klunk, W. E. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.009 · Cited by 26 · see citing works
Self-citationSnider, B. J., & Buckles, V. (2013) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000429171.50686.07 · Cited by 2 · see citing works
Self-citationPrice (1999) · doi:10.1002/1531-8249(199903)45:3
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853 · see citing works
Self-citationAmyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988 · see citing works
“In 2012, DIAN-TU launched the first prevention trial focusing on two drugs: gantenerumab (against Aβ aggregates) and solanezumab (against soluble Aβ monomers).(337) The data showed that gantenerumab had a positive impact on the reduction of cortical amyloid, leading to its further study by an exploratory open-label ex…”
BackgroundInfluentialDominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927 · see citing works
Self-citationTau and neurodegenerative disease: the story so far
Iqbal, K., Liu, F., & Gong, C.-X. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.225 · Cited by 806 · see citing works
Alzheimer’s disease prevention: from risk factors to early intervention
Crous‐Bou, M., Minguillón, C., Gramunt, N., & Molinuevo, J. L. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0297-z · Cited by 689 · see citing works
Lanoiselée, H.-M., Nicolas, G., Wallon, D., Rovelet-Lecrux, A., Lacour, M., Rousseau, S., Richard, A.-C., Pasquier, F., Rollin-Sillaire, A., Martinaud, O., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002270 · Cited by 616 · see citing works
Gordon, B. A., Blazey, T. M., Su, Y., Hari-Raj, A., Dincer, A., Flores, S., Christensen, J., McDade, E., Wang, G., Xiong, C., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30028-0 · Cited by 602 · see citing works
Self-citationSymptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis
Ryman, D. C., Acosta-Baena, N., Aisen, P. S., Bird, T., Danek, A., Fox, N. C., Goate, A., Frommelt, P., Ghetti, B., Langbaum, J. B. S., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000596 · Cited by 502 · see citing works
Self-citationAlzheimer’s Disease Genetics: From the Bench to the Clinic
Karch, C. M., Cruchaga, C., & Goate, A. M. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.041 · Cited by 473 · see citing works
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease
Salloway, S., Farlow, M., McDade, E., Clifford, D. B., Wang, G., Llibre-Guerra, J. J., Hitchcock, J. M., Mills, S. L., Santacruz, A. M., Aschenbrenner, A. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01369-8 · Cited by 359 · see citing works
Self-citationAlzheimer's disease associated with Down syndrome: a genetic form of dementia
Fortea, J., Zaman, S. H., Hartley, S., Rafii, M. S., Head, E., & Carmona-Iragui, M. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00245-3 · Cited by 357 · see citing works
Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer’s Disease
Baranello, R., Bharani, K., Padmaraju, V., Chopra, N., Lahiri, D., Greig, N., Pappolla, M., & Sambamurti, K. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666141218140953 · Cited by 331 · see citing works
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores
de Rojas, I., Moreno-Grau, S., Tesi, N., Grenier-Boley, B., Andrade, V., Jansen, I. E., Pedersen, N. L., Stringa, N., Zettergren, A., Hernández, I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22491-8 · Cited by 324 · see citing works
Bateman, R. J., Benzinger, T. L., Berry, S., Clifford, D. B., Duggan, C., Fagan, A. M., Fanning, K., Farlow, M. R., Hassenstab, J., McDade, E. M., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.07.005 · Cited by 303 · see citing works
Self-citationvan der Lee, S. J., Wolters, F. J., Ikram, M. K., Albert Hofman, D., Ikram, M. A., Amin, N., & van Duijn, C. M. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30053-x · Cited by 297 · see citing works
iPS cell technologies: significance and applications to CNS regeneration and disease
Okano, H., & Yamanaka, S. (2014) · Molecular Brain · doi:10.1186/1756-6606-7-22 · Cited by 232 · see citing works
Gordon, B. A., Blazey, T. M., Christensen, J., Dincer, A., Flores, S., Keefe, S., Chen, C., Su, Y., McDade, E. M., Wang, G., et al. (2019) · Brain · doi:10.1093/brain/awz019 · Cited by 180 · see citing works
Self-citationPast, present and future role of retinal imaging in neurodegenerative disease
Kashani, A. H., Asanad, S., Chan, J. W., Singer, M., Zhang, J., Sharifi, M., Khansari, M. M., Abdolahi, F., Shi, Y., Biffi, A., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100938 · Cited by 164 · see citing works
Shea, Y. F., Chu, L., Chan, A. O.-K., Ha, J. C. T., Li, Y., & Song, Y. (2015) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2015.08.004 · Cited by 137 · see citing works
Segregation of functional networks is associated with cognitive resilience in Alzheimer’s disease
Ewers, M., Luan, Y., Frontzkowski, L. K., Neitzel, J., Rubinski, A., Dichgans, M., Hassenstab, J. J., Gordon, B. A., Chhatwal, J. P., Levin, J., et al. (2021) · Brain · doi:10.1093/brain/awab112 · Cited by 137 · see citing works
Self-citationWeiner, M. W., Nosheny, R. L., Camacho, M. R., Truran‐Sacrey, D., Mackin, R. S., Flenniken, D., Ulbricht, A., Insel, P. S., Finley, S., Fockler, J., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.02.021 · Cited by 133 · see citing works
Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease
Thomas, J. B., Brier, M. R., Bateman, R. J., Snyder, A. Z., Benzinger, T. L., Xiong, C., Raichle, M., Holtzman, D. M., Sperling, R. A., Mayeux, R., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1654 · Cited by 129 · see citing works
Self-citationGenetic diagnosis and prognosis of Alzheimer’s disease: challenges and opportunities
Reitz, C. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1002469 · Cited by 120 · see citing works
Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years
Albert, M., Zhu, Y., Moghekar, A., Mori, S., Miller, M. I., Soldan, A., Pettigrew, C., Selnes, O., Li, S., & Wang, M.-C. (2018) · Brain · doi:10.1093/brain/awx365 · Cited by 118 · see citing works
Challenges of modifying disease progression in prediagnostic Parkinson's disease
Salat, D., Noyce, A. J., Schrag, A. E., & TOLOSA, E. S. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00060-0 · Cited by 118 · see citing works
Franzmeier, N., Düzel, E., Jessen, F., Büerger, K., Levin, J., Duering, M., Dichgans, M., Haass, C., Suárez‐Calvet, M., Fagan, A. M., et al. (2018) · Brain · doi:10.1093/brain/awy008 · Cited by 115 · see citing works
Self-citationAdvances in the prevention of Alzheimer's Disease
Sindi, S., Mangialasche, F., & Kivipelto, M. (2015) · F1000Prime Reports · doi:10.12703/p7-50 · Cited by 111 · see citing works
Toward precision medicine in Alzheimer’s disease
Reitz, C. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.03.05 · Cited by 100 · see citing works
Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer’s Disease
Chouraki, V., for the International Genomics of Alzheimer’s Project, Reitz, C., Maury, F., Bis, J. C., Bellenguez, C., Yu, L., Jakobsdottir, J., Mukherjee, S., Adams, H. H., et al. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150749 · Cited by 98 · see citing works
Anti-Viral Properties of Amyloid-β Peptides
Bourgade, K., Dupuis, G., Frost, E. H., & Fülöp, T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160517 · Cited by 96 · see citing works
Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward
Hsu, D. C., & Marshall, G. A. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160930112125 · Cited by 94 · see citing works
Plasma biomarkers predict Alzheimer’s disease before clinical onset in Chinese cohorts
Cai, H., Pang, Y., Fu, X., Ren, Z., & Jia, L. (2023) · Nature Communications · doi:10.1038/s41467-023-42596-6 · Cited by 92 · see citing works
CAP—advancing the evaluation of preclinical Alzheimer disease treatments
Reiman, E. M., Langbaum, J. B. S., Tariot, P. N., Lopera, F. J., Bateman, R. J., Morris, J. C., Sperling, R. A., Aisen, P. S. S., Roses, A. D., Welsh-Bohmer, K. A., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.177 · Cited by 91 · see citing works
Self-citationAdaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development
Paganoni, S., Berry, J. D., Quintana, M., Macklin, E. A., Saville, B. R., Detry, M. A., Chase, M. K., Sherman, A., Yu, H., Drake, K., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26285 · Cited by 89 · see citing works
Franzmeier, N., Ren, J., Damm, A., Monté, G. C., Boada, M., Ruiz, A., Ramı́rez, A., Jessen, F., Düzel, E., Rodríguez‐Gómez, O., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0404-6 · Cited by 86 · see citing works
Self-citationPanza, F., Solfrizzi, V., Imbimbo, B. P., & Logroscino, G. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.935332 · Cited by 76 · see citing works
Understanding the cause of sporadic Alzheimer’s disease
Zetterberg, H., & Mattsson, N. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.915740 · Cited by 73 · see citing works
Presymptomatic cortical thinning in familial Alzheimer disease
Weston, P. S. J., Nicholas, J. M., Lehmann, M., Ryan, N. S., Liang, Y., Macpherson, K., Marc Modat, A., Rossor, M. N., Schott, J. M., Sebastien Ourselin, A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003322 · Cited by 71 · see citing works
Bateman, R. J., Li, Y., McDade, E., Llibre‐Guerra, J. J., Clifford, D. B., Atri, A., Mills, S. L., Santacruz, A. M., Wang, G., Supnet, C. B., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00024-9 · Cited by 69 · see citing works
Self-citationMorris, J. C., Weiner, M., Xiong, C., Beckett, L., Coble, D., Saito, N., Aisen, P. S., Allegri, R., Benzinger, T. L. S., Berman, S. B., et al. (2022) · Brain · doi:10.1093/brain/awac181 · Cited by 68 · see citing works
Self-citationMallik, A. K., Drzezga, A. E., & Minoshima, S. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.005 · Cited by 62 · see citing works
Jiménez-Mesa, C., Arco, J. E., Martínez-Murcia, F. J., Suckling, J., Ramı́rez, J., & Górriz, J. M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106984 · Cited by 60 · see citing works
Molinuevo, J. L., Camı́, J., Carné, X., Carrillo, M. C., Georges, J., Isaac, M., Khachaturian, Z. S., Kim, S. Y. H., Morris, J. C., Pasquier, F., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.01.009 · Cited by 60 · see citing works
Self-citationAn intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice
Cheng, Y.-S., Chen, Z.-T., Liao, T., Lin, C. W., Shen, H. C.-H., Wang, Y., Chang, C., Liu, R., Chen, R. P. ‐., & Tu, P. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606666 · Cited by 60 · see citing works
Schultz, S. A., Strain, J. F., Adedokun, A., Wang, Q., Preische, O., Kühle, J., Flores, S. E., Keefe, S., Dincer, A., Ances, B. M., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104960 · Cited by 57 · see citing works
Self-citationFinsterwalder, S., Vlegels, N., Gesierich, B. G., Caballero, M. Á. A., Weaver, N. A., Franzmeier, N., Georgakis, M. K., Konieczny, M. J., Koek, H. L., Dominantly Inherited Alzheimer Network (DIAN), et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12150 · Cited by 56 · see citing works
Bussy, A., Snider, B. J., Coble, D. W., Xiong, C., Fagan, A. M., Cruchaga, C., Benzinger, T. L. S., Gordon, B. A., Hassenstab, J. J., Bateman, R. J., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.10.011 · Cited by 55 · see citing works
Self-citationKatzorke, A., Zeller, J. B. M., Müller, L. D., Lauer, M., Polak, T. T., Deckert, J., & Herrmann, M. J. (2018) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2018.02.003 · Cited by 54 · see citing works
Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease
Panza, F., Solfrizzi, V., Imbimbo, B. P., Giannini, M., Santamato, A., Seripa, D., & Logroscino, G. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.945522 · Cited by 51 · see citing works
Changes in Frailty Predict Changes in Cognition in Older Men: The Honolulu-Asia Aging Study
Armstrong, J. J., Godin, J., Launer, L. J., White, L. R., Mitnitski, A., Rockwood, K. J., & Andrew, M. K. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151172 · Cited by 51 · see citing works
Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer’s disease
Müller, S., Preische, O., Sohrabi, H. R., Gräber, S., Jucker, M., Dietzsch, J., Ringman, J. M., Martins, R. N., McDade, E., Schofield, P. R., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01327-w · Cited by 49 · see citing works
Self-citationJoseph‐Mathurin, N., Llibre‐Guerra, J. J., Li, Y., McCullough, A. A., Hofmann, C., Wojtowicz, J., Park, E., Wang, G., Preboske, G. M., Wáng, Q., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26511 · Cited by 48 · see citing works
Self-citationTorshizi, A. D., & Wang, K. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.015 · Cited by 47 · see citing works
From beta amyloid to altered proteostasis in Alzheimer’s disease
Bruni, A. C., Bernardi, L., & Gabelli, C. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101126 · Cited by 47 · see citing works
ENDPOINTS FOR PRE-DEMENTIA AD TRIALS: A REPORT FROM THE EU/US/CTAD TASK FORCE
Vellas, B. J., Bateman, R. J., Blennow, K., Frisoni, G. B., Johnson, K. A., Katz, R. G., Langbaum, J. B. S., Marson, D. C., Sperling, R. A., Wessels, A. M., et al. (2015) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2015.55 · Cited by 46 · see citing works
Self-citationPanza, F., Seripa, D., Lozupone, M., Solfrizzi, V., Imbimbo, B. P., Barulli, M. R., Tortelli, R., Capozzo, R., Bisceglia, P., Dimitri, A., et al. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1389885 · Cited by 41 · see citing works
Fernández, M. V., Liu, M., Beric, A., Johnson, M., Cetin, A., Patel, M. R., Budde, J., Kohlfeld, P., Bergmann, K., Lowery, J., et al. (2024) · Scientific Data · doi:10.1038/s41597-024-03485-9 · Cited by 41 · see citing works
Self-citationSchindler, S. E., & Fagan, A. M. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00142 · Cited by 39 · see citing works
Llibre‐Guerra, J. J., Li, Y., Schindler, S. E., Gordon, B. A., Fagan, A. M., Morris, J. C., Benzinger, T. L. S., Hassenstab, J. J., Wang, G., Allegri, R., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.17126 · Cited by 38 · see citing works
Self-citationComparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease
Dincer, A., Gordon, B. A., Hari‐Raj, A., Keefe, S., Flores, S. E., McKay, N. S., Paulick, A. M., Shady, K., Feldman, R. L., Hornbeck, R. C., et al. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102491 · Cited by 35 · see citing works
Self-citationMontine, T. J., & Montine, K. S. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20150656 · Cited by 34 · see citing works
Cerebrospinal fluid analysis in Alzheimer’s disease: technical issues and future developments
Lista, S., Zetterberg, H., Dubois, B., Blennow, K., & Hampel, H. J. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7366-z · Cited by 33 · see citing works
Diminishing return for mechanistic therapeutics with neurodegenerative disease duration?
Rubinsztein, D. C., & Orr, H. T. (2016) · BioEssays · doi:10.1002/bies.201600048 · Cited by 33 · see citing works
Genetic origin of a large family with a novel PSEN1 mutation (Ile416Thr)
Aguilar, L. R., Acosta‐Uribe, J., Giraldo, M., Moreno, S., Baena, A. Y., Alzate, D., Cuastumal, A. R., Aguillon, D. F., Madrigal, L., Saldarriaga, A., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.12.010 · Cited by 31 · see citing works
Trambauer, J., Sarmiento, R. M. R., Fukumori, A., Feederle, R., Baumann, K., & Steiner, H. (2019) · EMBO Reports · doi:10.15252/embr.201947996 · Cited by 31 · see citing works
A critical appraisal of blood-based biomarkers for Alzheimer’s disease
Lista, S., Mapstone, M. E., Caraci, F., Emanuele, E., López‐Ortiz, S., Martín-Hernández, J., Triaca, V., Imbimbo, C., Gabelle, A., Mielke, M. M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102290 · Cited by 30 · see citing works
O’Connor, A., Weston, P. S. J., Pavisic, I. M., Ryan, N. S., Collins, J. D., Lu, K., Crutch, S. J., Alexander, D. C., Fox, N. C., & Oxtoby, N. P. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00695-2 · Cited by 30 · see citing works
Imaging as a biomarker in drug discovery for Alzheimer’s disease: is MRI a suitable technology?
Pich, E. M., Jeromin, A., Frisoni, G. B., Hill, D., Lockhart, A., Schmidt, M. E., Turner, M. R., Mondello, S., & Potter, W. Z. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt276 · Cited by 29 · see citing works
Llibre‐Guerra, J. J., Li, Y., Allegri, R., Méndez, P. C., Surace, E. I., Rodríguez, J. J. L., Sosa, A. L., Aláez‐Verson, C., Longoria-Ibarrola, E. M., Téllez‐Martínez, J. A., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12227 · Cited by 29 · see citing works
Self-citationPathogenic variants in the Longitudinal Early‐onset Alzheimer's Disease Study cohort
Nudelman, K. N. H., Jackson, T., Rumbaugh, M. C., Eloyan, A., Abreu, M., Dage, J. L., Snoddy, C., Faber, K. M., Foroud, T., Hammers, D. B., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13482 · Cited by 28 · see citing works
Sosa, A. L., Brucki, S. M. D., Crivelli, L., Lopera, F. J., Acosta, D. M., Acosta‐Uribe, J., Aguilar, D., Aguilar-Navarro, S. G., Allegri, R., Bertolucci, P. H. F., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13850 · Cited by 28 · see citing works
Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies
Golde, T. E. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13583 · Cited by 28 · see citing works
Trambauer, J., Fukumori, A., & Steiner, H. (2020) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2020.01.011 · Cited by 28 · see citing works
11C-PiB PET can underestimate brain amyloid-β burden when cotton wool plaques are numerous
Abrahamson, E. E., Kofler, J., Becker, C. R., Price, J. C., Newell, K. L., Ghetti, B. F., Murrell, J. R., McLean, C., López, O. L., Mathis, C. A., et al. (2021) · Brain · doi:10.1093/brain/awab434 · Cited by 28 · see citing works
Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning
Castillo-Barnés, D., Su, L., Ramı́rez, J., Salas-Gonzalez, D., Martínez-Murcia, F. J., Illán, I. A., Segovia, F., Ortíz, A., Cruchaga, C., Farlow, M. R., et al. (2020) · Information Fusion · doi:10.1016/j.inffus.2020.01.001 · Cited by 28 · see citing works
Challenges of Integrative Disease Modeling in Alzheimer's Disease
Khatami, S. G., Robinson, C., Birkenbihl, C., Domingo‐Fernándéz, D., Hoyt, C. T., & Hofmann‐Apitius, M. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00158 · Cited by 27 · see citing works
δ-COP modulates Aβ peptide formation via retrograde trafficking of APP
Bettayeb, K., Chang, J. C., Luo, W., Aryal, S., Varotsis, D. F., Randolph, L. K., Netzer, W. J., Greengard, P., & Flajolet, M. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604156113 · Cited by 25 · see citing works
Takamatsu, Y., Ho, G. J., Koike, W., Sugama, S., Takenouchi, T., Waragai, M., Wei, J., Sekiyama, K., & Hashimoto, M. (2017) · npj Parkinson s Disease · doi:10.1038/s41531-016-0001-1 · Cited by 25 · see citing works
The landscape of autosomal-dominant Alzheimer’s disease: global distribution and age of onset
Liu, H., Marsh, T. W., Shi, X., Renton, A. E., Bowling, K. M., Ziegemeier, E., Wang, G., Cao, Y., Aristel, A., Li, J., et al. (2025) · Brain · doi:10.1093/brain/awaf038 · Cited by 24 · see citing works
Self-citationClinical heterogeneity in familial Alzheimer’s disease
van der Flier, W. M. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30275-7 · Cited by 23 · see citing works
Cerebrospinal Fluid Biomarkers in Familial Forms of Alzheimer's Disease and Frontotemporal Dementia
Rostgaard, N., Waldemar, G., Nielsen, J. E., & Simonsen, A. H. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000381828 · Cited by 22 · see citing works
Exosome release and cargo in Down syndrome
Hamlett, E. D., LaRosa, A., Mufson, E. J., Fortea, J., Ledreux, A., & Granholm, A. (2019) · Developmental Neurobiology · doi:10.1002/dneu.22712 · Cited by 21 · see citing works
Moga, D. C., Beech, B. F., Abner, E. L., Schmitt, F. A., Khouli, R. H. E., Martinez, A. I., Eckmann, L., Huffmyer, M. J., George, R., & Jicha, G. A. (2019) · Trials · doi:10.1186/s13063-019-3993-0 · Cited by 20 · see citing works
Prescott, J. W., Doraiswamy, P. M., Gamberger, D., Benzinger, T. L. S., Petrella, J. R., & for the Dominantly Inherited Alzheimer Network (2021) · Radiology · doi:10.1148/radiol.2021210383 · Cited by 20 · see citing works
Nanomedicine against Alzheimer’s and Parkinson’s Disease
Tandon, A., Singh, S. J., & Chaturvedi, R. K. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201021140904 · Cited by 19 · see citing works
Llibre‐Guerra, J. J., Iaccarino, L., Coble, D., Edwards, L., Li, Y., McDade, E., Strom, A., Gordon, B. A., Mundada, N. S., Schindler, S. E., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad280 · Cited by 19 · see citing works
Self-citationUpdate on Disease-Modifying/Preventive Therapies in Alzheimer’s Disease
Apter, J. T., Shastri, K., & Pizano, K. (2015) · Current Geriatrics Reports · doi:10.1007/s13670-015-0141-x · Cited by 18 · see citing works
Polak, T. T., Herrmann, M. J., Müller, L. D., Zeller, J. B. M., Katzorke, A., Fischer, M., Spielmann, F., Weinmann, E., Hommers, L. G., Lauer, M., et al. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1781-0 · Cited by 18 · see citing works
Grill, J. D., Bateman, R. J., Buckles, V., Oliver, A., Morris, J. C., Masters, C. L., Klunk, W. E., Ringman, J. M., & for the Dominantly Inherited Alzheimer’s Network (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0135-0 · Cited by 18 · see citing works
Self-citationBarriers to Effective Memory Assessments for Alzheimer’s Disease
Parra, M. A. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215445 · Cited by 17 · see citing works
Abnormal retinal capillary blood flow in autosomal dominant Alzheimer's disease
Singer, M., Ringman, J. M., Chu, Z., Zhou, X., Jiang, X., Shahidzadeh, A., Wang, R. K., & Kashani, A. H. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12162 · Cited by 16 · see citing works
White Matter Abnormalities Track Disease Progression in PSEN1 Autosomal Dominant Alzheimer’s Disease
Sánchez‐Valle, R., Monté, G. C., Sala‐Llonch, R., Bosch, B., Fortea, J., Lladó, A., Antonell, A., Balasa, M., Bargalló, N., & Molinuevo, J. L. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150899 · Cited by 16 · see citing works
A pathogenic PSEN1 Trp165Cys mutation associated with early-onset Alzheimer’s disease
Giau, V. V., Pyun, J., Suh, J., Bagyinszky, E., An, S. S. A., & Kim, S. (2019) · BMC Neurology · doi:10.1186/s12883-019-1419-y · Cited by 14 · see citing works
Genetic Heterogeneity of Alzheimer’s Disease: Embracing Research Partnerships
Nacmias, B., Bagnoli, S., Piaceri, I., & Sorbi, S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170570 · Cited by 14 · see citing works
Carmona‐Iragui, M., O’Connor, A., Llibre‐Guerra, J. J., Lao, P. J., Ashton, N. J., Fortea, J., & Sánchez‐Valle, R. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105327 · Cited by 13 · see citing works
Reiman, E. M., Pruzin, J. J., Ríos‐Romenets, S., Brown, C., Giraldo, M., Acosta‐Baena, N., Tobón, C., Hu, N., Chen, Y., Ghisays, V., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12843 · Cited by 13 · see citing works
Warren‐Gash, C., Cadogan, S. L., Nicholas, J. M., Breuer, J. M., Shah, D., Pearce, N., Shiekh, S., Smeeth, L., Farlow, M. R., Mori, H., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51669 · Cited by 11 · see citing works
Self-citation15 years of longitudinal genetic, clinical, cognitive, imaging, and biochemical measures in DIAN
Daniels, A. J., McDade, E., Llibre‐Guerra, J. J., Xiong, C., Perrin, R. J., Ibáñez, L., Supnet‐Bell, C., Cruchaga, C., Goate, A., Renton, A. E., et al. (2026) · npj Dementia · doi:10.1038/s44400-025-00047-7 · Cited by 11 · see citing works
Self-citationProof of concept demonstration of optimal composite MRI endpoints for clinical trials
Edland, S. D., Ard, M. C., Sridhar, J., Cobia, D. J., Martersteck, A., Mesulam, M. M., & Rogalski, E. J. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.05.002 · Cited by 11 · see citing works
The amyloid hypothesis is too good to be true
Kurkinen, M. T. (2017) · Alzheimer s Dementia & Cognitive Neurology · doi:10.15761/adcn.1000106 · Cited by 11 · see citing works
- Authors
- Moulder, K. L., Snider, B., Mills, S. L., Buckles, V. D., Santacruz, A. M., Bateman, R. J., & Morris, J. C.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Bateman, Randall J
- Morris, John C
- Venue
- Alzheimer's Research & Therapy
- Published
- 2013
- Volume
- 5
- Issue
- 5
- Pages
- 48
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC3978584
- OpenAlex
- W2110630889
- Cited by
- 142
- References
- 44
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 10 · 2023: 6 · 2022: 8 · 2021: 10 · 2020: 12 · 2019: 14 · 2018: 9 · 2017: 12 · 2016: 21 · 2015: 16 · 2014: 11
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Alzheimer s Research & Therapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- Deutsches Zentrum für Neurodegenerative Erkrankungen
- National Institute on Aging (U19AG032438)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- autosomal dominant Alzheimer's disease, mutation carriers, Alzheimer's disease biomarkers, preclinical Alzheimer's disease, longitudinal assessment, clinical trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
